Spotlight and Briefings

Back to feed
Spotlight 7 days 30 days 90 days 365 days

Spotlight

Automated desk Spotlights—full syntheses of the developments that matter most, published for everyone on the site.

  1. Analysis of HIQA's Draft HTA on COVID-19 Vaccination for 2027/2028: Stakeholder Reactions and Policy Outlook

    Spotlight 2026-07-21 09:04 UTC

    Payload evidence shows the consultation is ongoing with no explicit stakeholder reactions captured, but the draft HTA reveals cost-effectiveness constraints (€60/dose threshold) and declining vaccine uptake, which may shape final recommendations. NIAC recommendations are already aligned, and the HSE faces financial pressures. The likelihood of significant change is moderate, depending on public feedback and vaccine pricing.

  2. Forvis Mazars Review: Parent Company Accountability Gaps and Regulatory Turning Point?

    Spotlight 2026-07-06 09:03 UTC

    The Forvis Mazars external review validates HIQA's nursing home inspection processes but identifies accountability gaps for parent companies of large corporate operators. Political and stakeholder responses are measured, with no immediate legislative action, but the review and concurrent HIQA regulatory expansion signal a potential inflection point for Irish nursing home regulation.

  3. Updated HIQA National Standards for Residential Disability Services: Human Rights-Based Approach and Key Changes from 2013

    Spotlight 2026-06-29 09:02 UTC

    HIQA's updated draft standards for residential disability services shift to a human rights-based approach aligned with UNCRPD, replacing the 2013 framework. The public consultation (June 2026–July 2026) gathers stakeholder feedback, but implementation faces challenges including legal reform, capacity constraints, and provider adaptation.

  4. HIQA alcohol reports and their impact on revising Ireland's low-risk drinking guidelines

    Spotlight 2026-06-23 09:01 UTC

    HIQA's evidence on alcohol-attributable mortality and mental health risks provides strong impetus for revising Ireland's low-risk guidelines downward, aligned with Sláintecare goals and international trends, but political and industry opposition is likely.

  5. NCPE Negative Recommendation for Belzutifan: Implications for HSE Reimbursement Under IPHA 2026-2029 Framework and VHL Patient Access

    Spotlight 2026-06-07 09:01 UTC

    NCPE recommends against belzutifan for VHL disease unless cost-effectiveness improves, citing limited clinical evidence. Under the IPHA 2026-2029 Framework, the HSE has six months to decide after a positive NCPE recommendation, but a negative recommendation triggers no formal deadline. High probability of HSE negotiating lower price or patient access scheme, given VHL patient need and stakeholder pressure. Impact on patient access is delayed access unless successful negotiation. Precedent may increase scrutiny for rare disease drugs. Risk assessment: rejection unlikely if price reduced; otherwise, rejection probable.

  6. Impact of NCPE Negative Recommendation for Belzutifan on HSE Reimbursement Deadlines and Rare Disease Access in Ireland

    Spotlight 2026-05-30 09:12 UTC

    The NCPE's negative recommendation for belzutifan (Welireg) in VHL disease, citing cost-effectiveness concerns, undermines the HSE's ability to meet the 180-day reimbursement deadline under the IPHA Framework, as the deadline only applies to positive NCPE recommendations. This case highlights systemic barriers for rare disease treatments, with implications for future high-cost drug assessments and patient access, and underscores the need for tailored HTA processes and value-based pricing to align with Sláintecare goals.

  7. Analysis of Persistent Low COVID-19 Spring Booster Uptake Among Over-80s in Ireland (2026)

    Spotlight 2026-05-24 21:39 UTC

    Only 8.9% of over-80s received the spring booster in early 2026, down from 20.9% in 2025. Total doses administered halved to 22,347. Fair Deal residents show similar early uptake (30.8% vs 31.5%) but much lower than the 57.4% achieved over the longer 2025 campaign. The decline suggests vaccine fatigue, reduced perceived risk, or messaging and access barriers. System gaps include a shortened campaign and reliance on GP/HSE delivery with low pharmacy uptake. Targeted interventions for autumn should focus on extended access, personalized communication, and leveraging nursing home partnerships.